A mechanistic longitudinal model built on 28-week clinical trial data from type 2 diabetes patients receiving tirzepatide 15 mg (dual GIP/GLP-1 agonist) or semaglutide 1 mg (GLP-1 agonist) identifies the primary driver of tirzepatide's superior fasting glucose control: greater insulin-independent suppression of hepatic glucose production (HGP). HOMA-B beta-cell function initially rose then declined as insulin sensitivity improved — reversing canonical T2D progression. In low responders, deficient HGP suppression was the distinguishing feature, and simulated weight-loss enhancement accelerated early glycemic gains without improving long-term fasting glucose.
The finding reframes how we should think about GIP receptor co-agonism. The dominant clinical narrative attributed tirzepatide's advantage largely to amplified insulin secretion and greater weight loss — this model challenges both. The liver, not the pancreas, appears to be the decisive battlefield. That distinction carries real therapeutic weight: strategies targeting HGP suppression could benefit patients who respond poorly to existing agents without imposing the β-cell stress that accompanies chronic hypersecretion, a concern in progressive T2D. The insulin-independent HGP pathway likely involves direct hepatic GIP receptor signaling, an understudied mechanism that may explain why GIP addition to GLP-1 therapy produces disproportionate glycemic gains. Limitations include reliance on fasting-state measures only and the inherent constraints of computational modeling versus direct mechanistic measurement. Still, this is paradigm-shifting for drug development: it points toward liver-targeted combination strategies as the next frontier beyond weight-centric or incretin-centric thinking.